Fasslet al.,Science 375 , eabc1495 (2022) 14 January 2022 14 of 19
Additional target Inhibitor Immune
checkpoint
inhibitor
Tumor
type
Trial identifier
............................................................................................................................................................................................................................................................................................................................................
MEK Binimetinib BRAF V600-dependent
advanced solid tumors,
melanoma
NCT01543698, NCT02159066
............................................................................................................................................................................................................................................................................................................................................
PI3K Alpelisib Breast cancer with
PIK3CA mutation
NCT03439046
............................................................................................................................................................................................................................................................................................................................................
mTOR Everolimus Advanced dedifferentiated
liposarcoma, leiomyosarcoma,
glioma, astrocytoma,
glioblastoma, endometrial
carcinoma, pancreatic cancer,
neuroendocrine tumors
NCT03114527, NCT03355794,
NCT03834740, NCT03008408,
NCT02985125, NCT03070301
............................................................................................................................................................................................................................................................................................................................................
mTOR + inflammation............................................................................................................................................................................................................................................................................................................................................Everolimus + dexamethasone ALL NCT03740334
SHP2............................................................................................................................................................................................................................................................................................................................................TNO155 Advanced solid tumors NCT04000529
AR AR antagonists:
bicalutamide,
enzalutamide
TNBC, metastatic
prostate carcinoma
NCT03090165, NCT02555189
............................................................................................................................................................................................................................................................................................................................................
HDAC............................................................................................................................................................................................................................................................................................................................................Belinostat TNBC, ovarian cancer NCT04315233
proliferating cells Standard chemotherapy Ovarian cancer, metastatic
solid tumors, soft tissue
sarcoma, hepatocellular
carcinoma
NCT03056833, NCT03237390,
NCT03009201, NCT02524119
............................................................................................................................................................................................................................................................................................................................................
Abemaciclib
............................................................................................................................................................................................................................................................................................................................................
Aromatase Letrozole, anastrozole,
exemestane
HR+breast cancer,
metastatic breast
cancer, endometrial
cancer
NCT04256941, NCT03425838,
NCT04227327, NCT04393285,
NCT04305236, NCT03643510,
NCT03675893, NCT04352777,
............................................................................................................................................................................................................................................................................................................................................NCT04293393, NCT02057133
ER ER antagonists: fulvestrant Advanced breast cancer,
low-grade serous ovarian cancer
NCT03227328, NCT03531645,
............................................................................................................................................................................................................................................................................................................................................NCT04158362, NCT01394016
PD-1 Nivolumab,
pembrolizumab
Head and neck cancer,
gastroesophageal cancer,
NSCLC, HR+breast cancer
NCT04169074, NCT03655444,
NCT03997448, NCT02779751
............................................................................................................................................................................................................................................................................................................................................
ER + PD-L1 ER antagonists: fulvestrant Atezolizumab HR+breast cancer, metastatic
breast cancer
NCT03280563
............................................................................................................................................................................................................................................................................................................................................
AKT + ER + PD-L1 Ipatasertib + ER
antagonists: fulvestrant
Atezolizumab HR+breast cancer NCT03280563
............................................................................................................................................................................................................................................................................................................................................
PD-L1............................................................................................................................................................................................................................................................................................................................................LY3300054 Advanced solid tumors NCT02791334
HER2 Trastuzumab HER2+metastatic
breast cancer
NCT04351230
............................................................................................................................................................................................................................................................................................................................................
Receptor tyrosine
kinases
Sunitinib Metastatic renal
cell carcinoma
NCT03905889
............................................................................................................................................................................................................................................................................................................................................
IGF-1/IGF-2............................................................................................................................................................................................................................................................................................................................................Xentuzumab HR+breast cancer NCT03099174
VEGF-A............................................................................................................................................................................................................................................................................................................................................Bevacizumab Glioblastoma NCT04074785
PI3K Copanlisib HR+breast cancer, metastatic
breast cancer
NCT03939897
............................................................................................................................................................................................................................................................................................................................................
PI3K/mTOR............................................................................................................................................................................................................................................................................................................................................LY3023414 Metastatic cancer NCT01655225
ERK1/2 LY3214996 tumors with ERK1/2
mutations, glioblastoma,
metastatic cancer
NCT04534283, NCT04391595,
NCT02857270
............................................................................................................................................................................................................................................................................................................................................
Trilaciclib
............................................................................................................................................................................................................................................................................................................................................
Proliferating cells Chemotherapy SCLC: This trial evaluates the
potential clinical benefit of
trilaciclib in preventing
chemotherapy-induced
myelosuppression in patients
receiving chemotherapy
NCT04504513
............................................................................................................................................................................................................................................................................................................................................
continued on next page
RESEARCH | REVIEW